{"id":"W2121664617","doi":"10.1200/jco.2009.27.15_suppl.e16058","title":"A phase II study of single agent abraxane as second-line therapy in patients with advanced urothelial carcinoma","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Metastatic Urothelial Carcinoma; Tolerability; Internal medicine; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Progressive disease; Nausea; Adverse effect; Phases of clinical research; Oncology; Cancer; Paclitaxel; Urology; Gastroenterology; Surgery; Bladder cancer; Urothelial carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001658435,0.001390531,0.002742373,0.0004651067,0.000461881,0.001006652,0.0009956748,0.001617554,0.004285058],"category_scores_gemma":[0.001031855,0.0007597173,0.001036521,0.000410779,0.0008812429,0.0009875529,0.0003909021,0.003392674,0.0009640473],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000574778,"about_ca_system_score_gemma":0.001575679,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004906646,"about_ca_topic_score_gemma":0.00117429,"domain_scores_codex":[0.9996159,0.000179755,0.00002380553,0.00007145457,0.0000368222,0.00007225743],"domain_scores_gemma":[0.9991147,0.000147792,0.0001351825,0.00009745757,0.00007155503,0.0004332946],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5500478,0.2666227,0.007752364,0.001487952,0.0009961093,0.000594383,0.000691826,0.002937005,0.07493918,0.0003145031,0.003761739,0.08985453],"study_design_scores_gemma":[0.3697356,0.6185792,0.00635254,0.00002647648,0.0001579318,0.000300288,0.00006598067,0.0008496829,0.002262154,0.00009317481,0.001555987,0.00002094494],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941862,0.0009462454,0.0003516064,0.0002376668,0.0001071362,0.00291434,0.0004348864,0.00005296695,0.0007689192],"genre_scores_gemma":[0.9857104,0.001694734,0.002208769,0.0009320652,0.000217801,0.00483508,0.001486055,0.00002928116,0.002885655],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004285058,"threshold_uncertainty_score":0.01433498,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08418983834576428,"score_gpt":0.4412281365829351,"score_spread":0.3570382982371708,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}